Tab metoprolol dosage in adult
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Here is a comprehensive dosing reference for tablet metoprolol in adults:
Metoprolol Tablet — Adult Dosing
Metoprolol comes in two salt forms with different pharmacokinetics:
| Form | Brand Name | Frequency | Notes |
|---|---|---|---|
| Metoprolol tartrate (IR) | Lopressor | Twice daily (BID) or TID | Shorter-acting |
| Metoprolol succinate (XL/ER) | Toprol XL | Once daily | Extended-release, preferred |
By Indication
🫀 Hypertension
| Form | Starting Dose | Usual Range | Max Dose |
|---|---|---|---|
| Tartrate (IR) | 25–50 mg BID | 100–200 mg/day | 400 mg/day |
| Succinate (ER) | 25–50 mg once daily | 100–200 mg/day | 300 mg/day |
— Textbook of Family Medicine, Table 27-7
💔 Heart Failure with Reduced EF (HFrEF)
Only metoprolol succinate (extended-release) is approved for HF.
| Stage | Dose |
|---|---|
| Starting dose | 12.5–25 mg once daily |
| Target/max dose | 200 mg once daily |
| Titration | Increase every 2 weeks as tolerated |
Beta-blockers must be initiated at low doses and up-titrated gradually; ensure patient is euvolemic before starting. — Braunwald's Heart Disease
🫀 Acute Coronary Syndrome (ACS) / Angina
| Scenario | Dose |
|---|---|
| Stable, normotensive, no tachycardia | 25–50 mg orally every 6–8 hours initially |
| Maintenance | Titrate up to 100 mg twice daily to control heart rate, BP, and symptoms |
| High-risk / tachycardia / hypertension | IV metoprolol preferred (5 mg IV q5min × 3 doses) |
— Goldman-Cecil Medicine, ACS chapter
In patients with CAD + HFrEF, use carvedilol, long-acting metoprolol succinate, or bisoprolol only — agents proven to reduce mortality. — Fuster and Hurst's The Heart
🏥 Post-MI (Secondary Prevention)
- Metoprolol tartrate: 50–100 mg BID (started within 24h of hospitalization, continued indefinitely)
- Target: Resting HR 55–65 bpm
Key Clinical Points
- Titrate to heart rate: Target resting HR ≤60–65 bpm for angina, ≤70 bpm for HF
- Do not abruptly discontinue — taper over 1–2 weeks to avoid rebound ischemia/hypertension
- CKP/renal disease: No dose adjustment needed (hepatically metabolized via CYP2D6)
- Contraindications: Decompensated HF, severe bradycardia (<50 bpm), heart block (2nd/3rd degree), cardiogenic shock, severe reactive airway disease
Sources: Goldman-Cecil Medicine | Braunwald's Heart Disease | Textbook of Family Medicine | Fuster and Hurst's The Heart | Goodman & Gilman's Pharmacological Basis of Therapeutics
This is a shared conversation. Sign in to Orris to start your own chat.